Excelimmune, Inc. Presents Preclinical Data at ICAAC Demonstrating that Human Recombinant Polyclonal Antibody Therapy Provides Protection Against MRSA

WOBURN, Mass.--(BUSINESS WIRE)--Excelimmune, Inc. announced positive results from preclinical studies evaluating the efficacy of its human recombinant polyclonal antibody (HRPA) therapy against infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The results were presented in a poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The study demonstrated full immune protection against an otherwise 100% lethal dose of MRSA, and this result was achieved at an antibody concentration far lower than that typically required for monoclonal antibodies. MRSA is currently a leading cause of death due to infectious disease in the United States, surpassing deaths from HIV/AIDS-related infections and tuberculosis combined.